文章：

胶质母细胞瘤：蛋白质组学调查与生物样本库方法在多学科转化网络发展中的综述

Glioblastoma: Overview of Proteomic Investigations and Biobank Approaches for the Development of a Multidisciplinary Translational Network

原文发布日期：26 June 2025

DOI: 10.3390/cancers17132151

类型: Article

开放获取: 是

英文摘要：

Glioblastoma is a highly aggressive, infiltrative brain tumor of the central nervous system (CNS). Its extensive molecular and biochemical heterogenicity hinders the identification of reliable biomarkers and therapeutic targets, thereby making prognosis and existing therapy ineffective. In recent years, breakthroughs in the use of proteomics on a range of biological samples, such as plasma, cerebrospinal fluid (CSF), tissues, brain cells, and exosomes, represent a potential improvement to GBM investigations. Mass spectrometry-based approaches represent an important technique in the characterization of the tumoral proteome, for the identification of differentially expressed proteins, and for studying altered molecular pathways involved in tumor stages. Proteomics studies advance our knowledge about GBM pathogenesis, the discovery of reliable diagnostic and prognostic markers, and therapeutic approaches, also. In this context, for the effective application of proteomics on GBM, it is mandatory to develop a translational network by integrating hospitals, biobanks, and research institutions into a single network, to enable a collaborative approach across disciplines, thereby enabling rapid translation to clinical application of new proteomic insights. Today, high-quality biobanks play a key role in enabling collaborative, ethically compliant research, supporting the effective application of proteomics in glioblastoma studies and the translation of discoveries into clinical practice. This review explores current trends in proteomics and GBM research, highlighting how leveraging biobank infrastructure and fostering institutional cooperation can drive the development of targeted pilot projects to enhance the impact and effectiveness of glioblastoma research.

摘要翻译： 

胶质母细胞瘤是一种高度侵袭性、浸润性的中枢神经系统脑肿瘤。其广泛的分子和生化异质性阻碍了可靠生物标志物和治疗靶点的识别，从而导致预后不良且现有疗法效果有限。近年来，蛋白质组学在血浆、脑脊液、组织、脑细胞及外泌体等多种生物样本中的应用取得突破，为胶质母细胞瘤研究带来了潜在的改进。基于质谱的分析方法在表征肿瘤蛋白质组、识别差异表达蛋白以及研究肿瘤发展阶段中涉及的异常分子通路方面具有重要意义。蛋白质组学研究不仅增进了我们对胶质母细胞瘤发病机制的理解，也推动了可靠诊断与预后标志物的发现以及治疗策略的开发。在此背景下，为有效应用蛋白质组学于胶质母细胞瘤研究，必须构建转化网络，将医院、生物样本库及研究机构整合为统一体系，促进跨学科协作，从而加速新蛋白质组学发现向临床应用的转化。当前，高质量生物样本库在推动符合伦理的协作研究中发挥着关键作用，支持蛋白质组学在胶质母细胞瘤研究中的有效应用，并促进科研成果向临床实践转化。本综述探讨了蛋白质组学与胶质母细胞瘤研究的当前趋势，重点阐述如何利用生物样本库基础设施并加强机构合作，以推动针对性试点项目的开展，从而提升胶质母细胞瘤研究的影响力与实效性。

原文链接：

Glioblastoma: Overview of Proteomic Investigations and Biobank Approaches for the Development of a Multidisciplinary Translational Network